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Chronic hepatitis B virus (HBV) infection is still a
major health problem worldwide. In the past decade,
much progress has been made in the understanding and
management of chronic HBV infection and related liver
diseases. Most importantly, the introduction of universal
vaccination has signiﬁcantly reduced the incidence of
perinatal new HBV infection in most countries. In the
past decade, there have also been great advances in
the development of anti-viral therapy. Ideally, therapies
would be able to prevent adverse clinical outcomes such
as the development of cirrhosis, end-stage liver disease
and hepatocellular carcinoma. However, these clinical
endpoints typically take decades to occur and are therefore
impractical targets for clinical practice. As a result,
certain surrogate biomarkers that correlate with long-term
outcomes are frequently used to evaluate efﬁcacy of anti-
viral therapy. Of the serological and virological endpoints
that have been used, none has been shown to be ideal.
Suppression of viral replication, as measured by serum HBV
DNA levels, has been a major goal of therapy. Although
useful, the signiﬁcance of viral levels depends on the
stage of disease, degree of liver damage, and the type
of therapy. Besides, rebound of serum HBV DNA may occur
in a large proportion of patients receiving oral antiviral
agent. Hepatitis B e antigen (HBeAg) seroconversion is
still an important treatment endpoint in HBeAg-positive
patients. However, the durability of nucleos(t)ide analogue
treatment-related HBeAg seroconversion is not satisfactory;
and the emergence of HBeAg-negative disease is another
concern. Loss of hepatitis B surface antigen (HBsAg) is
considered close to the cure of the disease and is associated
with improved clinical outcomes; nevertheless it is rarely
achieved with current anti-vial therapies. Finally, liver
biopsy, traditionally considered as the gold standard, is
invasive, prone to sampling error, and not accepted by many
patients. In short summary, there is no ideal biomarker for
the evaluation of therapy for chronic hepatitis B. Patients
should be carefully monitored after stopping anti-viral
drugs. Challenges remain in the development of criteria for
treatment cessation and best treatment endpoints. HBsAg
quantitation is now being actively investigated for its role
in determining the natural history of CHB and whether the
on-treatment kinetics could predict response to anti-viral
therapy. The beneﬁt and limitations of using these endpoints
will be presented in this meeting.
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CS14.1 The risk of hepatocellular carcinoma in
HCV-related chronic hepatitis
M. Omata*. Yamanashi Central Hospital and University of
Tokyo, Japan
For the last 20 years, we are trying to elucidate the
natural courses of HCV infections from acute hepatitis to
the development of Hepatocellular Carcinoma. We have
followed 3000 patients almost 15 years, and it was found
that the progression of ﬁbrosis is a key component to
develop hepatocellular Carcinoma.
Furthermore, the eradication of HCV virus in fact regress
the extend ﬁbrosis and eventually reduce the cancer risk.
Recent molecular diagnostic analysis revealed certain
SNPs may predict the outcome of the development
of Hepatocellular Carcinoma by GWAS ( Genome Wide
Association Study). The genetic analysis may help us to
identify the individuals to the development Hepatocellular
Carcinoma more precisely in the future.
These strategies, along with the improvement of treatments
by themselves, are actually ending up now to the gradual
reduction of the Hepatocellular Carcinoma death in Japan.
CS14.2 Risk assessment of HBV-related HCC
development using liver stiffness measurement
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Background and Aims: Liver stiffness measurement (LSM)
using FibroScan accurately assesses the degree of liver
ﬁbrosis and the risk of hepatocellular carcinoma (HCC)
development in patients with chronic hepatitis C. This study
investigated the usefulness of LSM as a predictor of HCC
development in patients with chronic hepatitis B (CHB).
Methods: A total of 1,130 patients with non-biopsy-proven
CHB who underwent LSM between May 2005 and December
2007 were enrolled in this prospective study. After LSM was
performed, patients attended regular follow-up as part of
a surveillance program for the detection of HCC.
Results: The mean age of the patients (767 men, 363
women) was 50.2 years, and the median LSM was 7.7 kPa.
Six hundred seventy-two (59.5%) patients received antiviral
treatment before or after enrollment. During the follow-up
period (median, 30.7 months; range, 24.0 50.9 months),
HCC developed in 57 patients (2.0% per 1 person-year).
The 1-, 2-, and 3-year cumulative incidence rates of HCC
were 0.80%, 3.26%, and 5.98%, respectively. On multivariate
analysis, together with old age, male sex, heavy alcohol
consumption (>80 g/day), serum albumin, and hepatitis B
e antigen positivity, patients with a higher LSM (>8 kPa)
were at a signiﬁcantly greater risk of HCC development,
with the following hazard ratios: 3.07 (95% conﬁdence
interval [CI], 1.01 9.31; P = 0.047) for LSM 8.1 13 kPa; 4.68
(95%CI, 1.40 15.64; P = 0.012) for LSM 13.1 18 kPa; 5.55
